Drug Type Small molecule drug |
Synonyms VX 840, VX840 |
Target |
Action inhibitors |
Mechanism APOL1 inhibitors(Apolipoprotein L1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Apolipoprotein L1-mediated Kidney Disease | Phase 1 | United States | 07 Apr 2022 |